Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics
Islet amyloidosis by IAPP contributes to pancreatic β-cell death in diabetes, but the nature of toxic IAPP species remains elusive. Using concurrent time-resolved biophysical and biological measurements, we define the toxic species produced during IAPP amyloid formation and link their properties to...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2016-05-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/12977 |
id |
doaj-430cfdb339f14b1f94dfa0ddab3b017d |
---|---|
record_format |
Article |
spelling |
doaj-430cfdb339f14b1f94dfa0ddab3b017d2021-05-05T00:24:29ZengeLife Sciences Publications LtdeLife2050-084X2016-05-01510.7554/eLife.12977Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeuticsAndisheh Abedini0Annette Plesner1Ping Cao2Zachary Ridgway3Jinghua Zhang4Ling-Hsien Tu5Chris T Middleton6Brian Chao7Daniel J Sartori8Fanling Meng9Hui Wang10Amy G Wong11Martin T Zanni12C Bruce Verchere13Daniel P Raleigh14Ann Marie Schmidt15https://orcid.org/0000-0001-8902-070XDiabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, United StatesChild and Family Research Institute, Department of Pathology and Laboratory Medicine and Department of Surgery, University of British Columbia, Vancouver, CanadaDepartment of Chemistry, Stony Brook University, Stony Brook, United StatesDepartment of Chemistry, Stony Brook University, Stony Brook, United StatesDiabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, United StatesDepartment of Chemistry, Stony Brook University, Stony Brook, United StatesDepartment of Chemistry, University of Wisconsin-Madison, Madison, United StatesDiabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, United StatesDiabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, United StatesDepartment of Chemistry, Stony Brook University, Stony Brook, United StatesDepartment of Chemistry, Stony Brook University, Stony Brook, United StatesDepartment of Chemistry, Stony Brook University, Stony Brook, United StatesDepartment of Chemistry, University of Wisconsin-Madison, Madison, United StatesChild and Family Research Institute, Department of Pathology and Laboratory Medicine and Department of Surgery, University of British Columbia, Vancouver, CanadaDepartment of Chemistry, Stony Brook University, Stony Brook, United StatesDiabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, United StatesIslet amyloidosis by IAPP contributes to pancreatic β-cell death in diabetes, but the nature of toxic IAPP species remains elusive. Using concurrent time-resolved biophysical and biological measurements, we define the toxic species produced during IAPP amyloid formation and link their properties to induction of rat INS-1 β-cell and murine islet toxicity. These globally flexible, low order oligomers upregulate pro-inflammatory markers and induce reactive oxygen species. They do not bind 1-anilnonaphthalene-8-sulphonic acid and lack extensive β-sheet structure. Aromatic interactions modulate, but are not required for toxicity. Not all IAPP oligomers are toxic; toxicity depends on their partially structured conformational states. Some anti-amyloid agents paradoxically prolong cytotoxicity by prolonging the lifetime of the toxic species. The data highlight the distinguishing properties of toxic IAPP oligomers and the common features that they share with toxic species reported for other amyloidogenic polypeptides, providing information for rational drug design to treat IAPP induced β-cell death.https://elifesciences.org/articles/12977amylinIAPPoligomerdiabetesamyloidislet amyloid polypeptide |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Andisheh Abedini Annette Plesner Ping Cao Zachary Ridgway Jinghua Zhang Ling-Hsien Tu Chris T Middleton Brian Chao Daniel J Sartori Fanling Meng Hui Wang Amy G Wong Martin T Zanni C Bruce Verchere Daniel P Raleigh Ann Marie Schmidt |
spellingShingle |
Andisheh Abedini Annette Plesner Ping Cao Zachary Ridgway Jinghua Zhang Ling-Hsien Tu Chris T Middleton Brian Chao Daniel J Sartori Fanling Meng Hui Wang Amy G Wong Martin T Zanni C Bruce Verchere Daniel P Raleigh Ann Marie Schmidt Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics eLife amylin IAPP oligomer diabetes amyloid islet amyloid polypeptide |
author_facet |
Andisheh Abedini Annette Plesner Ping Cao Zachary Ridgway Jinghua Zhang Ling-Hsien Tu Chris T Middleton Brian Chao Daniel J Sartori Fanling Meng Hui Wang Amy G Wong Martin T Zanni C Bruce Verchere Daniel P Raleigh Ann Marie Schmidt |
author_sort |
Andisheh Abedini |
title |
Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics |
title_short |
Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics |
title_full |
Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics |
title_fullStr |
Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics |
title_full_unstemmed |
Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics |
title_sort |
time-resolved studies define the nature of toxic iapp intermediates, providing insight for anti-amyloidosis therapeutics |
publisher |
eLife Sciences Publications Ltd |
series |
eLife |
issn |
2050-084X |
publishDate |
2016-05-01 |
description |
Islet amyloidosis by IAPP contributes to pancreatic β-cell death in diabetes, but the nature of toxic IAPP species remains elusive. Using concurrent time-resolved biophysical and biological measurements, we define the toxic species produced during IAPP amyloid formation and link their properties to induction of rat INS-1 β-cell and murine islet toxicity. These globally flexible, low order oligomers upregulate pro-inflammatory markers and induce reactive oxygen species. They do not bind 1-anilnonaphthalene-8-sulphonic acid and lack extensive β-sheet structure. Aromatic interactions modulate, but are not required for toxicity. Not all IAPP oligomers are toxic; toxicity depends on their partially structured conformational states. Some anti-amyloid agents paradoxically prolong cytotoxicity by prolonging the lifetime of the toxic species. The data highlight the distinguishing properties of toxic IAPP oligomers and the common features that they share with toxic species reported for other amyloidogenic polypeptides, providing information for rational drug design to treat IAPP induced β-cell death. |
topic |
amylin IAPP oligomer diabetes amyloid islet amyloid polypeptide |
url |
https://elifesciences.org/articles/12977 |
work_keys_str_mv |
AT andishehabedini timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT annetteplesner timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT pingcao timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT zacharyridgway timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT jinghuazhang timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT linghsientu timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT christmiddleton timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT brianchao timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT danieljsartori timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT fanlingmeng timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT huiwang timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT amygwong timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT martintzanni timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT cbruceverchere timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT danielpraleigh timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics AT annmarieschmidt timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics |
_version_ |
1721476366477557760 |